A dual-target drug comprising paclitaxel and the PFKFB3 inhibitor, PFK15, blocked cancer-associated fibroblast-mediated cancer cell growth and reduced the lactate concentration in the TME [193]. The gene discussed is PFKFB3; the disease is cancer.